Ameliorative Effect of Myricetin on Nonalcoholic Fatty Liver Disease in ob/ob Mice
- PMID: 34668765
- DOI: 10.1089/jmf.2021.K.0090
Ameliorative Effect of Myricetin on Nonalcoholic Fatty Liver Disease in ob/ob Mice
Abstract
Obesity, insulin resistance, and oxidative stress are important risk factors for nonalcoholic fatty liver disease (NAFLD). This study aimed at determining the beneficial effects of myricetin against NAFLD in ob/ob mice. C57BL/6-Lepob/ob mice (n = 21) were fed an AIN-93G diet (ob/ob control group) or diet containing 0.04% (low myricetin; LMTN group) or 0.08% (high myricetin; HMTN group) myricetin, and lean heterozygous littermates (lean control group, n = 7) were fed AIN-93G diet for 10 weeks. HMTN consumption significantly lowered serum glucose levels and homeostasis model assessment for insulin resistance values in ob/ob mice. In addition to reducing serum triglyceride (TG) and cholesterol levels, HMTN significantly decreased total hepatic lipid and TG levels partly through downregulation of carbohydrate response element-binding protein and sterol regulatory element-binding protein 1c expression. The reduction in the levels of hepatic thiobarbituric acid reactive substances by HMTN likely resulted from the elevation of nuclear factor erythroid-2-related factor 2 expression. Tumor necrosis factor-α and monocyte chemoattractant protein 1 expressions were reduced by LMTN and HMTN, and HMTN also decreased interleukin-6 expression. These results suggest that myricetin has beneficial effects against NAFLD by regulating the expression of transcription factors of hepatic lipid metabolism, the antioxidant system, and pro-inflammatory cytokines.
Keywords: insulin resistance; myricetin; nonalcoholic fatty liver disease (NAFLD); oxidative stress; pro-inflammatory cytokine.
Similar articles
-
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.Free Radic Biol Med. 2019 Sep;141:192-204. doi: 10.1016/j.freeradbiomed.2019.06.019. Epub 2019 Jun 18. Free Radic Biol Med. 2019. PMID: 31226399
-
Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5. Metabolism. 2013. PMID: 23928105
-
Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis.Eur J Pharmacol. 2012 Sep 15;691(1-3):9-18. doi: 10.1016/j.ejphar.2012.06.021. Epub 2012 Jun 26. Eur J Pharmacol. 2012. PMID: 22742899
-
FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c.Lipids Health Dis. 2019 Nov 15;18(1):197. doi: 10.1186/s12944-019-1132-2. Lipids Health Dis. 2019. PMID: 31729980 Free PMC article.
-
Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.Am J Gastroenterol. 2003 Sep;98(9):2093-7. doi: 10.1111/j.1572-0241.2003.07670.x. Am J Gastroenterol. 2003. PMID: 14499793 Review.
Cited by
-
Recent studies on myricetin and its biological and pharmacological activities.EXCLI J. 2023 Nov 28;22:1223-1231. doi: 10.17179/excli2023-6571. eCollection 2023. EXCLI J. 2023. PMID: 38317860 Free PMC article. No abstract available.
-
Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease.Front Pharmacol. 2022 Sep 16;13:1005312. doi: 10.3389/fphar.2022.1005312. eCollection 2022. Front Pharmacol. 2022. PMID: 36188561 Free PMC article. Review.
-
Myricetin (3,3',4',5,5',7-Hexahydroxyflavone) Prevents 5-Fluorouracil-Induced Cardiotoxicity.ACS Omega. 2022 Jan 25;7(5):4514-4524. doi: 10.1021/acsomega.1c06475. eCollection 2022 Feb 8. ACS Omega. 2022. PMID: 35155943 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
